Lyme Disease Association, Inc. PO Box 1438, Jackson, New Jersey 08527 888-366-6611
[email protected] 732-938-7215 (Fax) LymeDiseaseAssociation.org Conflicts of Interest in Lyme Disease: Laboratory Testing, Vaccination, and Treatment Guidelines © 2001 Lyme Disease Association, Inc. All rights reserved. Contact: LDA PO Box 1438 Jackson, NJ 08527 Conflicts of Interest in Lyme Disease: Treatment, Laboratory Testing, and Vaccination Lyme Disease Association, Inc. April 2001 TABLE OF CONTENTS EXECUTIVE SUMMARY PART ONE: A Lyme Disease Primer Section I Symptoms and Scope of Lyme Disease Section II The Scientific Debates Section III History: A Story of Medicine and Politics Section IV Watershed at Dearborn Section V The Lyme Vaccine PART TWO: LYME DISEASE AS BUSINESS MODEL Section VI Why Lyme Had to be Redefined in Order for Products to Reach Market Section VII Lyme Disease Products and Companies Section VIII Lyme Disease Patents Section IX Size of the Lyme Disease Market in US Dollars PART THREE: CONFLICTS OF INTEREST IN LYME DISEASE POLICY Section X Defining Conflict of Interest Section XI Laboratory Diagnosis and Conflict of Interest Section XII Vaccine and Conflict of Interest Section XIII Treatment Guidelines and Conflict of Interest CONCLUSION PART FOUR: NOTES AND REFERENCES EXECUTIVE SUMMARY For more than a decade, Lyme disease has been the object of debate. On one side are academicians, pharmaceutical companies, and government agencies, who claim the disease is usually mild and virtually always easily cured. On the other side are chronic Lyme disease patients and their doctors, who say that infection may survive the standard four weeks of antibiotic treatment, and that its impact may be debilitating and difficult to treat.